Form 4 for PFE Pfizer
Accepted 2022-02-25 00:00:00 ET · period of report 2022-02-23 · accession 0001225208-22-003470 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-25 | 2022-02-23 | PFE | McDermott Michael | EVP | M - OptEx | $27.34 | +15.0K | 81.5K | +22% | +$408.8K |
| DM | 2022-02-25 | 2022-02-23 | PFE | McDermott Michael | EVP | F - Tax | $50.03 | -10.3K | 78.6K | -12% | -$516.7K |
| D | 2022-02-25 | 2022-02-23 | PFE | McDermott Michael | EVP | M - OptEx | $0.00 | -15.0K | 0 | -100% | $0 |
| DM | 2022-02-25 | 2022-02-24 | PFE | McDermott Michael | EVP | A - Grant | $0.00 | +64.3K | 34.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-23 | M | A | 14,952 | $27.34 | 81,518 | D | — | — | (F1) The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| 2 | Common | Common Stock | 2022-02-23 | F | D | 7,401 | $51.28 | 71,190 | D | — | — | (F3) The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). (F4) Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| 3 | Common | Common Stock | 2022-02-23 | F | D | 2,927 | $46.87 | 78,591 | D | — | — | (F2) The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| 4 | Derivative | Stock Appreciation Rights | 2022-02-23 | M | D | 14,952 | $0.00 | 0 | D | $27.34 · 2022-02-23 to 2022-02-23 | 14,952 Common Stock | (F5) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
| 5 | Derivative | Stock Appreciation Rights | 2022-02-24 | A | A | 30,109 | $0.00 | 30,109 | D | $45.96 · 2029-02-24 to 2029-02-24 | 30,109 Common Stock | (F6) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |
| 6 | Derivative | Stock Appreciation Rights | 2022-02-24 | A | A | 34,234 | $0.00 | 34,234 | D | $45.96 · 2027-02-24 to 2027-02-24 | 34,234 Common Stock | (F5) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |